WATERLOO, ONTARIO--(Marketwire - Sept. 22, 2010) - Huron Technologies, a developer of world leading technology for digital pathology and DNA microarray solutions, today announced the following corporate and management changes.
Confocal Inc. has acquired a controlling interest in Huron Technologies. Confocal Inc. was founded by Dr. Savvas Chamberlain, Mike Panayi, and Dr. Ted Dixon, and has been capitalized by a new infusion of equity capital provided by Dr. Savvas Chamberlain and Mike Panayi. Huron Technologies remains the operating company and is a subsidiary of Confocal Inc.
Recently the board of directors announced the new officers of Huron Technologies as follows: Dr. Savvas Chamberlain: Acting Chief Executive Officer, Mike Panayi: Chief Financial Officer, Audil Virk: Chief Operating Officer, Dr. Savvas Damaskinos: Chief Technology Officer, Dr. Ted Dixon: V.P. Science & Technology.
Dr. Savvas Chamberlain founded DALSA in 1980. He is a member of the Order of Canada, Fellow of the Royal Society of Canada and Fellow of the IEEE. He was the CEO of DALSA from its inception until August 2007. He served as Executive Chairman and CTO until October 2009. Presently he is Chairman of the board. Under his leadership DALSA has grown worldwide from few employees to more than 1000 employees worldwide with revenues of $206 million in 2008. During his tenure as CEO he was responsible for corporate strategy, strategic technology direction, long-term planning, and setting the direction of the company's culture. Dr. Chamberlain has published more than 150 papers in refereed journals and he is the author or co-author of more than 20 patents in the area solid state image sensors.
Mike Panayi brings significant financial experience in growing companies from their infancy to profitability. Audil Virk contributes energy and knowledge in the management of day to day operations. Dr. Savvas Damaskinos and Dr. Ted Dixon provide extensive experience in the science and technology of instruments for digital pathology.
Dr. Savvas Chamberlain: "I am quite excited in leading the Huron Technologies team. Huron Technologies has a world leading technology which can be used to advance cancer research for the benefit of our society. Huron Technologies now has the resources to move from a research laboratory to an enterprise business and is well positioned to commercialize its unique technology internationally".
Dr. Martin Yaffe, Senior Scientist at Sunnybrook Research Institute, said "We have two TISSUEscope scanners in our research laboratory, and they are very useful in breast cancer research. The unique ability of the TISSUEscope to digitize a whole-mount breast tissue slide (5" x 7") with 0.5 micron pixels has enabled us to produce images that would otherwise have been impossible."
Dr. Aaron Fenster, Imaging Director at Robarts Research Institute, said "The TISSUEscope has reduced the time to collect 3-D image planes from large specimens from months to a few days. It has accelerated our research allowing us to perform projects we could only dream about in the past."
About Huron Technologies
Huron Technologies is a pioneer of confocal technology applied to an instrument which has been used successfully in digital pathology for cancer research and other research applications. The Huron Technologies TISSUEscope instrument can be presently found in research laboratories such as Sunnybrook Health Sciences Centre, Robarts Research Institute, MaRS in Canada, and in other research labs in the USA.